Neurol. praxi. 2014;15(6):300-304

What›s new on the issue of „women and epilepsy”?

MUDr. Jana Zárubová
Neurologická klinika 2. LF UK a FN Motol, Praha

Comprehensive clinical approach to women with epilepsy requires consideration of special pathophysiological, diagnostic, therapeutic and social aspects. The aim is to understand and apply this knowledge to allow women with epilepsy live the same life as their peers or with the least possible handicap. Presented update is a sequel of „Woman and epilepsy“ 2nd edition, (EpiStop, 2010), where the topic was delt with in great detail and in multidisciplinary way. Each subtopic of the article includes summary and current data and is accompanied with clinical commentary.

Keywords: woman and epilepsy, reproductive and sexual dysfunction, contraception, pregnancy, menopause, osteopathy

Published: December 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zárubová J. What›s new on the issue of „women and epilepsy”? Neurol. praxi. 2014;15(6):300-304.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Edlow JA, Caplan LR, O´Brien K, Tibbles CD. Diagnosis of acute neurological emergencies in pregnant and post-partum women. Lancet Neurol 2013; 12: 175-185. Go to original source... Go to PubMed...
    2. EpiStop. Žena a epilepsie. FreshConcept s.r.o. 2010.
    3. EpiStop. Soubor minimálních diagnostických a terapeutických standardů u pacientů s epilepsií. FreshConcept, Praha; 2013: 37-39.
    4. Hill M, Vrbíková J, Zárubová J, Kancheva R, Velíková M, Kancheva L, Kubátová J, Dušková M, Marusič P, Pařízek A, Stárka L. The steroid metabolome in lamotrigine-treated women with epilepsy. Steroids. 2011; 76(12): 1351-1357. Go to original source... Go to PubMed...
    5. Hill M, Vrbíková J, Zárubová J, Vceláková H, Dusková M, Kancheva R, Kubátová J, Stárka L. Sulphates of 3beta-hydroxy-5-ene steroids in women with epilepsy. Prague Med Rep. 2010; 111(2): 111-126. Go to PubMed...
    6. Harden CL, Pennell PB. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013; 12(1): 72-83. Erratum in: Lancet Neurol. 2013 Feb; 12 (2): 128. Dosage error in article text. Go to original source... Go to PubMed...
    7. Herzog AG1, Fowler KM, Sperling MR, Liporace JD, Kalayjian LA, Heck CN, Krauss GL, Dworetzky BA, Pennell PB. Progesterone Trial Study Group. Variation of seizure frequency with ovulatory status of menstrual cycles. Epilepsia. 2011; 52(10): 1843-1848.
    8. Johnston CA, Crawford PM. Anti-epileptic drugs and hormonal treatments. Curr Treat Options Neurol. 2014; 16(5): 288. Go to original source... Go to PubMed...
    9. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013; 6(10): 1221-1286. Go to original source... Go to PubMed...
    10. Kuba R. Sexuální dysfunkce u pacientů s epilepsií. Neurol. praxi, 2006; 4: 196-198.
    11. Lindhout D. Antiepileptic drugs during pregnancy and cognitive outcomes The Lancet Neurology, 2013; 12(3): 219-220. Go to original source... Go to PubMed...
    12. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW. NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244-252. Go to original source... Go to PubMed...
    13. Pennel PB. Pregancy, Epilepsy and Women´s Issues.Continuum (Minneap Minn) 2013; 19(3): 697-714. Go to original source... Go to PubMed...
    14. Rauchenzauner M, Bitsche G, Svalheim S, Tauboll E, Haberlandt E, Wildt L, Rostasy K, Luef G. Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children-results from a pilot study. Epilepsy Res. 2010; 88(2-3): 264-268. Go to original source... Go to PubMed...
    15. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav. Feb 2013; 63(2): 254-266. Go to original source... Go to PubMed...
    16. Reisinger TL1, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.Epilepsy Behav. 2013; 29(1): 13-18. Go to PubMed...
    17. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand. 2012; 126(1): e1-4. Go to original source... Go to PubMed...
    18. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10(7): 609-617. Go to original source... Go to PubMed...
    19. Tomson T1, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013; 54(3): 405-414.
    20. Veiby G1, Daltveit AK, Schj?lberg S, Stoltenberg C, ?yen AS, Vollset SE, Engelsen BA, Gilhus NE. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54(8): 1462-1472.
    21. Zárubová J. Těhotenství. Prekoncepční období. V Žena a Epilepsie. EpiStop 2010: 50-55.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.